Fresh off a clinical setback,

ImClone

(IMCL)

and partner

Bristol-Myers

(BMY) - Get Report

reportedly plan at least three large trials on their experimental cancer treatment Erbitux in the coming year.

One of the studies, a 200-patient investigation of the drug's efficacy in treating colorectal cancer, will begin in the next few weeks, published reports said. The FDA in December refused to consider Erbitux for treatment of colon cancer because of deficiencies in the studies backing it.

ImClone shares fell this week following release of a study showing little difference in head and neck cancer patients treated with a chemotherapy drug and Erbitux than those on a placebo over two months.